HealthEx Cell and Gene Therapy is designed for C-suite and board level executives who are developing and commercialising cell and gene therapies for treatment of a variety of diseases.

This is a 40-person Chatham House Rule, formatted forum in which industry leaders discuss and shape the future of their sector behind closed doors. They are hollow-square formats and not your standard one-dimensional meeting format meaning all executives engage in meaningful strategic and sector debate and discussion. The forums will address the key industry challenges head on, providing genuine outcomes for the executives and the sector as a whole.

The 40 seats will be allocated with no fewer than 36 executives and KOLs, with the remaining seats taken by  Forum Co-Hosts that may include 1 Pharma, 1 Global Advisory, 1 Law Firm, 1 CRO and / or 1 Investor. The GEO breakdown will roughly be 40 US, 50% UK and EU and 10% RoW and as we are focused on diversity, we are looking to ensure that at least 30% of the attendees are women Executives.

CXO and board level executives of companies advancing and commercialising cell and gene therapies, KOLs and commercial leaders, Pharma cell and gene therapy leaders, senior representatives from payers, government, regulatory and leading sector investors

CEOs and/or event partners put forward case studies – either success stories or current challenges - and use the group as “consultants”. Each case study follows this format:

Headline – short and enticing
Nutshell – a concise statement of the issue
Background – the players, the issue, what was at stake, etc
What Was Tried? - what worked and what didn’t
Questions - clarifying questions from the group.
Peer Consultation
Review - what are you taking back with you? what will you try?

The Industry and Business Agenda

Pricing, reimbursement and CoGs, promoting the long-term value of currently expensive therapies to the whole system (payers, systems, patients, families, society) , preparing an effective supply chain, differing market access by geography

The R&D Agenda

Getting more advanced therapies to market quicker, increasing efficiencies in clinical trials, reducing costs in trials, patient ID and recruitment, increasing convincing clinical results

The Investment Agenda

Attracting investment in to cell and gene therapy, educating investors on the value proposition of companies and technology (risks and rewards), highlighting the reward

The Future Agenda

Partnerships and collaboration models for advancing the sector, bringing down the cost of goods, making successful cell and gene therapies commonplace in the clinicians arsenal, applying advances to new diseases

Are you interested in a seat at the table and would like to be considered for an invitation to attend the HealthEx World Forum?